GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Simcere Pharmaceutical Group Ltd (HKSE:02096) » Definitions » Other Current Assets

Simcere Pharmaceutical Group (HKSE:02096) Other Current Assets : HK$82 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Simcere Pharmaceutical Group Other Current Assets?

Simcere Pharmaceutical Group's other current assets for the quarter that ended in Dec. 2023 was HK$82 Mil.

Simcere Pharmaceutical Group's quarterly other current assets increased from Dec. 2022 (HK$30 Mil) to Jun. 2023 (HK$41 Mil) and increased from Jun. 2023 (HK$41 Mil) to Dec. 2023 (HK$82Mil).

Simcere Pharmaceutical Group's annual other current assets declined from Dec. 2021 (HK$199 Mil) to Dec. 2022 (HK$30 Mil) increased from Dec. 2022 (HK$30 Mil) to Dec. 2023 (HK$82 Mil).


Simcere Pharmaceutical Group Other Current Assets Historical Data

The historical data trend for Simcere Pharmaceutical Group's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Simcere Pharmaceutical Group Other Current Assets Chart

Simcere Pharmaceutical Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Current Assets
Get a 7-Day Free Trial 457.06 1,255.70 198.86 29.53 81.66

Simcere Pharmaceutical Group Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 198.86 84.99 29.53 40.72 81.66

Simcere Pharmaceutical Group Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


Simcere Pharmaceutical Group Other Current Assets Related Terms

Thank you for viewing the detailed overview of Simcere Pharmaceutical Group's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Simcere Pharmaceutical Group (HKSE:02096) Business Description

Traded in Other Exchanges
Address
No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu, Nanjing, CHN, 210042
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production and commercialization of pharmaceuticals focused on generic pharmaceuticals. It has a diversified product portfolio focused on therapeutic areas, including, oncology (including cell therapy), nervous system diseases, autoimmune diseases and antiinfection. The company's products include Endostar, Enweida, Iremod, Sanbexin and Others.
Executives
Wang Xi 2305 Beneficiary of a trust
Ren Jinsheng 2202 Interest of your spouse
Right Wealth Holdings Limited 2501 Other
Wang Xi 2501 Other
Simcere Investments Group Limited 2501 Other
Excel Investments Group Limited 2501 Other
Simcere Pharmaceutical Holding Limited 2501 Other
Simcere Holding Limited 2501 Other
Artking Global Limited 2501 Other
Ren Zhen 2501 Other
Ren Yong 2501 Other
Ren Weidong 2501 Other
Peng Suqin 2501 Other
P&h Holdings Group Ltd. 2501 Other
Li Shimeng 2501 Other

Simcere Pharmaceutical Group (HKSE:02096) Headlines

No Headlines